Heyholder
‹ Activism Filings

SAMSUNG BIOLOGICS CO.,LTD. Q3 revenue KRW 1,490.3 billion, operating profit KRW 640.1 billion

SAMSUNG BIOLOGICS CO.,LTD.· Periodic Report

AI summary · Not investment advice

Samsung Biologics sold KRW 1,490.3 billion in Q3 and earned KRW 640.1 billion from its main business, up 1.0% from a year earlier and up 9.1% from the previous quarter.

Operating profit · 3 months

KRW 640.1 billion

Key facts

Revenue (3 months)
KRW 1.5 trillion
Net income (3 months)
KRW 391.1 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 1.3 trillion
Revenue (year to date)
KRW 4.1 trillion
Operating profit (prior-year 3 months)
KRW 633.5 billion
Operating profit (year to date)
KRW 1.8 trillion
Net income (prior-year 3 months)
KRW 574.5 billion
Net income (year to date)
KRW 1.3 trillion

Commentary

AI commentary · Not investment advice

What happened

Samsung Biologics reported its third-quarter results on a consolidated basis, covering the 3 months and the year to date from January 1 to September 30, 2026.

In the company's terms

Revenue for the 3 months was KRW 1,490.3 billion. That is 18.5% higher than the same period a year earlier (KRW 1,257.5 billion). It is also 12.8% higher than the previous quarter.

What changes for shareholders

Operating profit (profit from the core business) for the 3 months was KRW 640.1 billion. That is 1.0% higher than a year earlier (KRW 633.5 billion) and 9.1% higher than the previous quarter.

Net income (the final profit after taxes and all other costs) for the 3 months was KRW 391.1 billion. That is 31.9% lower than a year earlier (KRW 574.5 billion) and 9.2% lower than the previous quarter.

For the year to date, revenue was KRW 4,068.4 billion, operating profit was KRW 1,807.3 billion, and net income was KRW 1,291.0 billion.

Comments

No comments yet

Comments from shareholders will appear here.